FDA approves Astellas' gastric cancer therapy
Adds pricing and availability in paragraph 4
By Sriparna Roy
Oct 18 (Reuters) -The U.S. Food and Drug Administration approved Astellas' 4503.T therapy to treat a type of gastric cancer, the health regulator's website showed on Friday.
The therapy, branded as Vyloy, was approved to be used in combination with a type of chemotherapy for patients with a type of cancer which begins in the gastroesophageal junction, where the esophagus and stomach meet.
Gastric cancer accounts for about 1.5% of all new cancers diagnosed in the United States each year, according to the American Cancer Society.
Vyloy will be available through specialty distributors in about 6-12 business days at a list price of $1600.00 per 100 milligram vial, Astellas said, adding that treatment costs per patient could vary.
It was approved in Japan in March and became the first targeted therapy to be approved in the world for a type of family of proteins that binds to cancerous cells commonly seen in gastric cancers.
Britain's health regulator in August approved the therapy to be used in patients whose gastric or gastro-oesophageal junction cancer cannot be removed by surgery, or has spread to other parts of the body.
Roche ROG.S said on Friday that the FDA had approved its companion diagnostic test to identify patients who may be eligible for Vyloy.
The FDA had previously declined to approve the therapy, citing issues related to a third-party manufacturer.
The therapy, chemically known as zolbetuximab, is a monoclonal antibody which can attach itself to certain cancer cells and destroy them. When studied in combination with other chemotherapies in late-stage trials, it improved survival in patients compared to placebo.
Other approved drugs for patients with advanced gastric or gastroesophageal cancer include AstraZeneca AZN.L and Daiichi Sankyo's 4568.T Enhertu and Merck's MRK.N Keytruda.
Reporting by Sriparna Roy, Sneha S K and Mariam Sunny in Bengaluru; Editing by Maju Samuel
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
